Optimi Health Reports Early Clinical Rollout of Natural Psilocybin Capsules for Treatment-Resistant Depression in Australia

Vancouver, British Columbia--(Newsfile Corp. - February 26, 2026) - Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FSE: 8BN) ("Optimi" or the "Company"), a Health Canada-licensed manufacturer of pharmaceutical-grade psychedelic drug products, today reported that patients diagnosed with treatment-resistant depression (TRD) have now been treated in Australia using the Company's naturally derived 5 mg psilocybin capsules under the Authorised Prescriber Scheme.

The clinical administration follows the Company's first psilocybin shipment of 2026 and represents the early rollout of Optimi's finished drug product across authorised clinics operating within Australia's nationally regulated access framework. Product was dispensed through Optimi's licensed Australian pharmacy partner pursuant to approved import permits prior to clinical administration. Treatments were administered by Authorised Prescribers in accordance with Australian regulatory requirements.

This milestone occurs approximately six months following Optimi's initial commercial launch of psilocybin supply into Australia and reflects early-stage clinical adoption within the regulated access pathway. Prior to this, the Company completed multiple MDMA shipments for supply under Australia's Authorised Prescriber Scheme. Optimi is now supplying both psilocybin for TRD and MDMA for PTSD into Australia's nationally regulated medical framework.

Both products are produced at Optimi's accredited facility in Canada and comply with the Therapeutic Goods Administration (TGA) Quality Guidelines, including TGO 112 and TGO 113, where applicable.

"We are seeing the Authorised Prescriber pathway function as intended — enabling regulated access for eligible patients under appropriate clinical oversight," said Ilan Hayman of Mind Medicine Australia. "The early administration of psilocybin-assisted therapy under this framework reflects careful implementation by clinicians and the continued maturation of Australia's regulated access model."

Treatment data and patient-reported outcomes are being captured through Australia's national registry in partnership with Australian National University. Psilocybin-assisted therapy in Australia is prescribed through authorised programs supported by Mind Medicine Australia.

Clinicians, hospital networks, and authorised programs operating under the Authorised Prescriber Scheme may seek information regarding access through Mind Medicine Australia at info@mindmedicineaustralia.org.

For global enquiries outside of Australia, please contact sales@optimihealth.ca.

For more information, please contact:Dane Stevens, CEOOptimi Health Corp.(778) 761-4551investors@optimihealth.ca www.optimihealth.ca